BizJournals Portfolio
Home >   Business Views, Opinions and Blogs >   Business Blogs >   Tech Observer >  

Questcor From Orphan Drug To Orphan Stock

Tech Observer

by Blaise Zerega
Main
Last Bytes: Yahoo, Facebook, Apple, MySpace   Last Bytes: Google, Amazon.com, San Fran Muni-Hacker Update...

Recent Blog Posts

Links

Jul 23 2008 12:00am EDT

Questcor: From Orphan Drug To Orphan Stock?

Blaise Zerega can't fathom an 1,800% price hike.  Russ Mitchell's examination yesterday of why Questcor Pharmaceuticals raised the price of a drug used to treat infantile epilepsy from $1,600 per vial to $23,000 per vial helps set the stage for Congressional hearings tomorrow. But in the meanwhile, the company's share price is already taking a hit, down 9% to $4.57 as of this posting. What if it QCOR shares eventually fell 1,800%? Instant karma, anyone?

. □

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.


Connect With Portfolio.com
Like Portfolio on Facebook

Come on, like us—you know you want to.

Follow Portfolio on Twitter

Follow us and if you're an innovative entrepreneur, we'll return the favor.

The Mix

Today's top stories, conversation starters, and the back nine business bites.

spotlight on

Slideshows

500 Startups Hits New York

Dave McClure's brainchild makes its way to New York and introduces East Coast money folks to some intriguing new companies. View Slideshow